Five years ago this summer, AstraZeneca ($AZN) decided to pony up to purchase Maryland-based MedImmune for a cool $15.6 billion, a deal that left many wondering whether the bills matched the product. Now, incoming CEO Pascal Soriot has his work cut out for him.
Come October, the French-native will jump over from Roche ($RHHBY), where he served as chief operating officer since 2010. He's inheriting a vaccines and biotech drugs division with 2,600 Maryland employees and 4,000 globally, The Washington Post reports. The company will also shutter two California offices, leading to a loss of 200 jobs and a shift of 100 more to other sites.